To read the full article sign up for free or sign in.

Legend signs $1B T-cell therapy deal with Novartis

Nov. 13, 2023

Legend Biotech Corp. is entering what it no doubt hopes will be another fruitful collaboration with big pharma. Legend’s wholly owned subsidiary, Legend Biotech Ireland Ltd., will work with Novartis AG in an exclusive global development and license agreement for chimeric antigen receptor T-cell therapies targeting DLL3.

BioWorld Deals and M&A CAR T Cancer

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 21, 2025.

Coinfections and diversity paint the many shades of HIV cure

BioWorld

We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...

Engineered IL-18 variants with improved drug-like properties show promise for cancer immunotherapy

BioWorld Science

Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in promoting antitumor immunity by activating T and natural killer (NK) cells....

For big pharma, China is a shopper’s dream

BioWorld

Big pharma is increasingly shopping in China to fill its pipelines as it faces looming patent cliffs on major blockbusters coupled with growing pricing...